Abbvie (ABBV) PT Lowered to $84 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $261.72 --0%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 14 | New: 22
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 14 | New: 22
Join SI Premium – FREE
Morgan Stanley analyst David Risinger lowered the price target on Abbvie (NYSE: ABBV) to $84.00 (from $88.00) while maintaining a Equalweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie completes $10.9B acquisition of Apogee Therapeutics
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- AbbVie Completes Acquisition of Apogee Therapeutics
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
